GenTarget

GenTarget is a private, early-revenue biotech firm operating as a research tools and services provider, not a therapeutic developer. Its core business revolves around manufacturing and selling lentiviral vectors and engineered cell lines for academic and industrial research, with a strong emphasis on supporting the immuno-oncology and immunotherapy fields. The company appears to be in a commercial stage for its research products, catering to the pre-clinical research market with tools for CAR-T, TCR, CRISPR, and gene expression studies. Its model is service and platform-based, providing essential reagents to accelerate therapeutic discovery elsewhere.

Lentiviral vector engineering and production platform for gene delivery, supporting overexpression, knockdown (shRNA/miRNA), CRISPR gene editing, and cell line engineering. Integrated with AI/ML for design optimization.

GenTarget competes with large life science tools companies (e.g., Thermo Fisher, Sartorius) offering viral vectors, as well as numerous specialized contract research organizations (CROs) and biotech vendors focused on viral vector production and cell line engineering. Its differentiation lies in its specific focus on lentivirus and curated product lines for immuno-oncology.